NOF to Exhibit and Present Poster at SITC 2024
NOF to Exhibit and Present Poster at SITC 2024
Houston, TX, USA (November 08 - 09, 2024)
10/24/2024
NOF CORPORATION is pleased to announce its participation in the upcoming SITC 2024, which will be held at George R. Brown Convention Center, Houston, TX, U.S.A. from November 6 to 10.
The Conference website: https://www.sitcancer.org/2024...
As a part of the event, NOF CORPORATION will showcase its products for Drug Delivery System at Booth #712 from November 8 to 9.
In addition, Satoshi Kishida, Research Scientist at NOF CORPORATION, will give a poster presentation.
Title
IL-2 mutein conjugated by cutting-edge PEG can improve the antitumor activity of CD8+ T cells in the tumor microenvironment
Date & Time
November 9 from 9:00 to 20:30, CST
Place
Exhibit Halls AB-George R. Brown Convention Center, #948
Speaker
Satoshi Kishida, Research Scientist, NOF CORPORATION
Abstract
IL-2 can activate CD8+ T cells and is well-known as a promising immune- oncology agent. However,
its therapeutic efficacy is limited due to its short half-life and IL-2 receptor alpha (IL-2Ra)
capability. Moreover, the activation of CD8+ T cells by IL-2 is suppressed in the tumor
microenvironment (TME)
due to the acidic condition. Therefore, long-acting IL-2, which reduces IL-2Ra capability and
improves the antitumor activity of CD8+ T cells in the TME, is desired to enhance the therapeutic
efficacy of IL-2. Here, we developed IL-2 mutein, which has reduced IL-2Ra capability, and found
that IL-2 mutein
conjugated by cutting-edge PEG can improve antitumor activity of CD8+ T
cells in acidic conditions by in vitro assay, such as cell proliferation assay and cell killing
assay, rather than IL-2 mutein conjugated by conventional PEG.
NOF CORPORATION invites attendees to visit booth #712 to explore their innovative drug delivery solutions and engage with their experts.
For further information or to arrange a meeting, please refer to the following contact information.